The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

Table 2

Comparison of predominately physical concepts of health-related quality of life (HRQoL) during rilonacept and placebo treatments. (b) Comparison of predominately psychosocial concepts of health-related quality of life (HRQoL) during rilonacept and placebo treatments.

(a)

HRQoL concept	*Rilonacept mean (SD)	*Placebo mean (SD)	Rilonacept-placebo differences (SD)	𝑃 value
PhS	33.66 (16.41)	23.7 (14.51)	9.58 (3.69)	0.025
PF	68.18 (28.54)	52.31 (26)	16.01 (6.45)	0.031
BP	59.55 (31.99)	44.17 (23.39)	14.61 (6.81)	0.055
GH	42.12 (16.52)	37.26 (13.85)	3.84 (3.54)	0.30
RP	70.45 (30.83)	52.08 (35.21)	17.09 (8.64)	0.074

∗Higher score is better (score of 0–100).
PhS: physical summary score; PF: physical function; BP: bodily pain and discomfort; GH: general health perceptions; RP: role/social limitations due to physical health.

(b)

HRQoL concept	*Rilonacept mean (SD)	*Placebo mean (SD)	Rilonacept-placebo differences (SD)	𝑃 value
PsS	51.4 (10.31)	49.79 (12.37)	1.4 (2.27)	0.55
REB	74.75 (30.9)	57.41 (33.84)	15.25 (8.58)	0.10
BE	78.37 (16.13)	81.74 (15.05)	−3.57 (3.35)	0.31
MH	77.95 (14.45)	76.3 (19.14)	1.15 (2.88)	0.70
SE	80.11 (20.25)	73.61 (22.54)	7.32 (4.19)	0.11
PE	67.05 (23.07)	61.11 (26.43)	5.96 (5.64)	0.31
PT	74.75 (28.31)	67.13 (29.76)	7.35 (7.69)	0.36

∗Higher score is better (score of 0–100).
PsS: psychosocial summary score; REB: role/social limitations due to emotional or behavioral difficulties; BE: behavior; MH: mental health; SE: self-esteem; PE: emotional impact on parent/patient; PT: parental/patient time impact.